Horizon Discovery Group PLC (LON:HZD)‘s stock had its “buy” rating restated by investment analysts at N+1 Singer in a report released on Tuesday. They presently have a GBX 194 ($2.53) price objective on the stock. N+1 Singer’s target price would suggest a potential upside of 17.58% from the stock’s current price.

HZD has been the subject of several other research reports. Numis Securities Ltd reissued a “buy” rating and issued a GBX 252 ($3.29) price objective on shares of Horizon Discovery Group PLC in a research note on Wednesday, June 1st. Panmure Gordon reissued a “buy” rating and issued a GBX 270 ($3.52) price objective on shares of Horizon Discovery Group PLC in a research note on Wednesday, June 1st. Finally, Beaufort Securities reissued a “speculative buy” rating on shares of Horizon Discovery Group PLC in a research note on Friday, September 2nd. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of GBX 217.25 ($2.84).

Shares of Horizon Discovery Group PLC (LON:HZD) opened at 153.40 on Tuesday. The company has a 50-day moving average of GBX 160.39 and a 200 day moving average of GBX 160.58. The company’s market capitalization is GBX 144.33 million. Horizon Discovery Group PLC has a 52-week low of GBX 125.00 and a 52-week high of GBX 188.06.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/horizon-discovery-group-plc-hzd-earns-buy-rating-from-n1-singer.html

About Horizon Discovery Group PLC

Horizon Discovery (LSE: HZD) is a world-leading gene editing company that designs and engineers genetically-modified cells, applying them in research and clinical applications to advance human health. Horizon’s proprietary gene editing platform, able to alter almost any gene sequence, has generated a catalogue of over 23,000 cell and in vivo models that recapitulate the genetic anomalies found in diseases like cancer.

Receive News & Ratings for Horizon Discovery Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Discovery Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.